Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes (January 2021)
Umesh Dashora, Robert Gregory, Peter Winocour, Ketan Dhatariya, Susannah Rowles, Andrew Macklin, Gerry Rayman, Dinesh Nagi, Katie Whitehead, Hannah Beba, Parijat De, Dipesh Patel
Abstract
Sodium glucose co-transporter 2 (SGLT2) inhibitors are now an established class of medications for the treatment of type 2 diabetes (T2D), no longer reserved for use by specialists in diabetes. They are being used increasingly for their cardiac and renal benefits by primary care, cardiology and renal teams for indications in parallel with diabetes care as part of holistic management. This guidance provides essential information on SGLT therapy, including the main advantages and the important risks of which healthcare professionals should be aware.
Topics & Concepts
MedicineDiabetes mellitusType 2 diabetesPosition statementHealth professionalsIntensive care medicineStatement (logic)Health careFamily medicineInternal medicineEndocrinologyEconomicsPolitical scienceEconomic growthLawDiabetes Treatment and ManagementMetabolism, Diabetes, and CancerDiabetes Management and Research